Introducing the world’s smallest, simplest, most sustainable single dose inhaler

Immediate, convenient, sustainable relief

Too many people lack access to the drugs they need to relieve their suffering. While access for others remains problematic.

The 1nhaler is designed to provide relief to millions of people across the globe. By harnessing the latest developments in inhalable dry powder technology, we have produced the world’s first membrane-based delivery technology. This allows us to create a device that transforms from a portable 2D shape into a 3D inhaler.

It’s faster acting. Simpler to use. Cheaper to manufacture. Easier to distribute. And won’t cost the earth.

  • Packaging design (illustrative only)

  • 1nhaler in 3D ‘activated’ state

  • Convenient and discreet

  • Packaging design (illustrative only)

  • Packaging design (illustrative only)

  • Clinician and patient friendly

  • Packaging design (illustrative only)

  • User-centric simplicity

The first membrane based dry powder delivery system

  • No blisters

  • No capsules

  • No reservoirs

By utilising a unique patented membrane-based dispersion technology, we are able to remove the issue of agglomeration and, as a result, remove the need for aerosolisation chambers.

This allows us to create a device that can be manufactured in a two-dimensional shape, offering all of the benefits of simplicity of use, sustainability, affordability and portability.

Simple

A patient-centric device that requires just two actions to operate: squeeze and breathe.

Sustainable

The 1nhaler is constructed from 100% recyclable materials, with 95% of the device made from cardboard.

Affordable

The 1nhaler will have the lowest cost per unit of any single dose dry powder inhaler.

Portable

The size a credit card, the 1nhaler is uniquely portable for users and highly distributable for manufacturers.

To learn more about the 1nhaler technology, please get in touch.

We are actively seeking partnerships, and we’d love to hear from you.

Meet the Team

  • Lisa McMyn

    Chief Executive Officer

  • Helen Muirhead

    Chief Scientific Officer

  • Don Smith

    Chief Innovation Officer

  • Khadija Schwach

    Business Development Director

  • Joanne Kelley

    Board Director

  • Indrė Statkevičienė

    MPD Project Lead

  • Gordon Muirhead

    Expert Advisor

Our mission, like our device, is simple

To improve access to pharmaceutical treatments for more people around around the world – affordably and sustainably.